Sun Pharmaceutical Industries announced that the US FDA has granted its subsidiary final approval for its Abbreviated New Drug Applications (ANDA) for generic version of Prevacid, Lansoprazole delayed-release capsules USP, 15 mg and 30 mg.
Lansoprazole delayed-release capsules USP, 15 mg and 30 mg are therapeutic equivalents of Takeda’s prevacid delayed-released capsules. These capsules have annual sales of approximately $430 million in the US. Lansoprazole delayed-release capsules USP are indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer.
EP News Bureau – Mumbai